Juan Graham Acquires 33,333 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Juan Graham acquired 33,333 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The shares were bought at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the purchase, the chief financial officer now directly owns 35,354 shares in the company, valued at $79,546.50. The trade was a 1,649.33 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Perspective Therapeutics Stock Down 8.0 %

Shares of NYSE:CATX opened at $1.96 on Wednesday. The stock’s 50-day moving average is $2.88 and its 200-day moving average is $6.10. Perspective Therapeutics, Inc. has a 52-week low of $1.90 and a 52-week high of $19.05.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday. Royal Bank of Canada cut their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, March 27th. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Finally, Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $14.44.

Hedge Funds Weigh In On Perspective Therapeutics

Large investors have recently added to or reduced their stakes in the company. FMR LLC boosted its stake in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $4,132,000. State Street Corp increased its stake in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after acquiring an additional 1,192,812 shares during the period. Octagon Capital Advisors LP raised its position in Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares in the last quarter. Finally, Affinity Asset Advisors LLC lifted its stake in Perspective Therapeutics by 160.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after purchasing an additional 800,000 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.